Apellis Pharmaceuticals, Inc.
Clinical trials sponsored by Apellis Pharmaceuticals, Inc., explained in plain language.
-
New hope for kidney transplant patients: drug aims to prevent early organ failure
Disease control Recruiting nowThis study is testing whether an investigational drug called pegcetacoplan can help prevent a common complication called delayed graft function (DGF) after a kidney transplant. DGF means the new kidney doesn't work right away, often requiring temporary dialysis. The trial will en…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo aims to halt blinding eye disease
Disease control Recruiting nowThis study is testing whether adding a new investigational drug called APL-3007 to an existing treatment (Syfovre) can better slow the progression of geographic atrophy, a late-stage form of age-related macular degeneration that causes permanent vision loss. About 240 participant…
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC